Cel-Sci Corp (CVM) 0.84 $CVM
The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Wed Feb 11, 7:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Philippines Regulatory Agency (PFDA) has cleared the Company to commence patient enrollment of the Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the Philippines. Three hospitals in the Philippines are expected to join the study.
CVM: 0.84 (-0.01)
CEL-SCI posts higher net loss of USD7.845m for Q1 2015
M2 - Mon Feb 09, 5:43AM CST
Immunotherapeutic company CEL-SCI (NYSE MKT:CVM) stated on Friday that its net loss was USD7.845m (USD0.09 per basic common share) for the first quarter ended 31 December 2014.
CVM: 0.84 (-0.01)
Cel-Sci EPS of -$0.11
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 3:52PM CST
CVM: 0.84 (-0.01)
CEL-SCI Corporation Reports First Quarter 2015 Financial Results
Business Wire - Fri Feb 06, 3:40PM CST
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2014.
CVM: 0.84 (-0.01)
CEL-SCI to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Thu Feb 05, 7:03AM CST
CEL-SCI Corporation (NYSE MKT:CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:00 p.m. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
CVM: 0.84 (-0.01)
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Probio Invest - at Seeking Alpha - Mon Feb 02, 3:37PM CST
CVM: 0.84 (-0.01), PSTI: 2.91 (+0.01), ORMP: 4.58 (+0.16)
CeL-Sci's Innovative Cancer Killer Featured in February Issue of PharmaVOICE
ACCESSWIRE - Mon Feb 02, 8:32AM CST
LOS ANGELES, CA / ACCESSWIRE / February 3, 2015 / On the heels of announcing another record monthly patient enrollment in its Phase III Head and Neck Cancer Trial, Geert Kersten, the CEO of CEL-SCI Corporation (NYSE MKT:CVM) is featured in the February issue of PharmaVOICE, a print publication for life-sciences executives and other healthcare-service related professionals.
CVM: 0.84 (-0.01)
CEL-SCI Reports Record Monthly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Mon Feb 02, 7:30AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that in January it enrolled 24 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This marks a record month for enrollment. 352 patients have been enrolled in the study as of January 31, 2015.
CVM: 0.84 (-0.01)
CEL-SCI Corp. (CVM) in Focus: Stock Adds 7.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 7:51AM CST
CEL-SCI Corporation (CVM) was a big mover last session, as the company saw its shares rise by almost 8% on the day.
CVM: 0.84 (-0.01), AMAG: 41.49 (+0.23)
CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania
Business Wire - Mon Jan 26, 8:00AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced the Romanian Ministry of Health has cleared the Company to begin patient enrollment and conduct its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Romania.
CVM: 0.84 (-0.01)
Investors look to Lighten Up on Shares of CEL-SCI, Shares Down 6.8% (CVM)
Comtex SmarTrend(R) - Mon Jan 12, 10:11PM CST
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 6.8% to $0.68 on 1.0x average daily volume. Thus far today, CEL-SCI has traded 275,000 shares, vs. average volume of 271,000 shares per day. The stock has underperformed the Dow (-6.8% to the Dow's -0.7%) and underperformed the S&P 500 (-6.8% to the S&P's -0.9%) during today's trading.
CVM: 0.84 (-0.01)
Updated Coverage Report Focuses on CEL-SCI Corporation
Marketwired - Mon Jan 12, 6:32AM CST
CEL-SCI Corporation (NYSE MKT: CVM) is the subject of an updated coverage report by Acceleron Equity Research, a stock market research firm focused on emerging companies and technologies.
CVM: 0.84 (-0.01)
CEL-SCI to Present at Biotech Showcase 2015
Business Wire - Fri Jan 09, 7:30AM CST
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA.
CVM: 0.84 (-0.01)
Date Set for Arbitration Trial Between CEL-SCI and Clinical Research Organization inVentiv
Business Wire - Tue Jan 06, 7:02AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that the trial in its ongoing arbitration against inVentiv Clinical, LLC (f/k/a PharmaNet, LLC and PharmaNet GmbH (f/k/a PharmaNet AG)), a clinical research organization, is currently scheduled for May 4, 2015.
CVM: 0.84 (-0.01)
Traders Get Bullish on Shares of CEL-SCI, Shares Up 8.5% (CVM)
Comtex SmarTrend(R) - Mon Jan 05, 11:35AM CST
CEL-SCI (AMEX:CVM) is one of today's best performing penny stocks, up 8.5% to $0.67 on 1.1x average daily volume. Thus far today, CEL-SCI has traded 308,000 shares, vs. average volume of 283,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's -1.7%) and outperformed the S&P 500 (8.5% to the S&P's -1.7%) during today's trading.
CVM: 0.84 (-0.01)
Cell-Sci updates Phase 3 enrollment numbers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 9:53AM CST
CVM: 0.84 (-0.01)
CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold over 2013 in its Phase III Head and Neck Cancer Trial
Business Wire - Mon Jan 05, 7:31AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that in 2014 it enrolled close to 200 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This annual enrollment represents an eight-fold increase over enrollment of 24 patients in 2013, the year during which CEL-SCI dismissed its prior clinical research organization (CRO) and replaced it with new CROs, Aptiv and Ergomed. Twenty one (21) patients were enrolled in the study during the month of December.
CVM: 0.84 (-0.01)
CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments
Business Wire - Tue Dec 23, 3:30PM CST
CEL-SCI Corporation (NYSE MKT: CVM) reported financial results today for the fiscal year ended September 30, 2014. The Company also reported key clinical and corporate developments achieved during, and subsequent to, fiscal 2014.
CVM: 0.84 (-0.01)
The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Wed Feb 11, 7:00AM CST
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Philippines Regulatory Agency (PFDA) has cleared the Company to commence patient enrollment of the Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the Philippines. Three hospitals in the Philippines are expected to join the study.
CVM: 0.84 (-0.01)
CEL-SCI posts higher net loss of USD7.845m for Q1 2015
M2 - Mon Feb 09, 5:43AM CST
Immunotherapeutic company CEL-SCI (NYSE MKT:CVM) stated on Friday that its net loss was USD7.845m (USD0.09 per basic common share) for the first quarter ended 31 December 2014.
CVM: 0.84 (-0.01)
Cel-Sci EPS of -$0.11
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 3:52PM CST
CVM: 0.84 (-0.01)
CEL-SCI Corporation Reports First Quarter 2015 Financial Results
Business Wire - Fri Feb 06, 3:40PM CST
CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended December 31, 2014.
CVM: 0.84 (-0.01)
CEL-SCI to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Thu Feb 05, 7:03AM CST
CEL-SCI Corporation (NYSE MKT:CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 4:00 p.m. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference will take place February 9-10 at the Waldorf Astoria in New York City.
CVM: 0.84 (-0.01)
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Probio Invest - at Seeking Alpha - Mon Feb 02, 3:37PM CST
CVM: 0.84 (-0.01), PSTI: 2.91 (+0.01), ORMP: 4.58 (+0.16)
CeL-Sci's Innovative Cancer Killer Featured in February Issue of PharmaVOICE
ACCESSWIRE - Mon Feb 02, 8:32AM CST
LOS ANGELES, CA / ACCESSWIRE / February 3, 2015 / On the heels of announcing another record monthly patient enrollment in its Phase III Head and Neck Cancer Trial, Geert Kersten, the CEO of CEL-SCI Corporation (NYSE MKT:CVM) is featured in the February issue of PharmaVOICE, a print publication for life-sciences executives and other healthcare-service related professionals.
CVM: 0.84 (-0.01)
CEL-SCI Reports Record Monthly Patient Enrollment in Its Phase III Head and Neck Cancer Trial
Business Wire - Mon Feb 02, 7:30AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that in January it enrolled 24 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This marks a record month for enrollment. 352 patients have been enrolled in the study as of January 31, 2015.
CVM: 0.84 (-0.01)
CEL-SCI Corp. (CVM) in Focus: Stock Adds 7.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 7:51AM CST
CEL-SCI Corporation (CVM) was a big mover last session, as the company saw its shares rise by almost 8% on the day.
CVM: 0.84 (-0.01), AMAG: 41.49 (+0.23)
CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania
Business Wire - Mon Jan 26, 8:00AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced the Romanian Ministry of Health has cleared the Company to begin patient enrollment and conduct its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in Romania.
CVM: 0.84 (-0.01)
Investors look to Lighten Up on Shares of CEL-SCI, Shares Down 6.8% (CVM)
Comtex SmarTrend(R) - Mon Jan 12, 10:11PM CST
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 6.8% to $0.68 on 1.0x average daily volume. Thus far today, CEL-SCI has traded 275,000 shares, vs. average volume of 271,000 shares per day. The stock has underperformed the Dow (-6.8% to the Dow's -0.7%) and underperformed the S&P 500 (-6.8% to the S&P's -0.9%) during today's trading.
CVM: 0.84 (-0.01)
Updated Coverage Report Focuses on CEL-SCI Corporation
Marketwired - Mon Jan 12, 6:32AM CST
CEL-SCI Corporation (NYSE MKT: CVM) is the subject of an updated coverage report by Acceleron Equity Research, a stock market research firm focused on emerging companies and technologies.
CVM: 0.84 (-0.01)
CEL-SCI to Present at Biotech Showcase 2015
Business Wire - Fri Jan 09, 7:30AM CST
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA.
CVM: 0.84 (-0.01)
Date Set for Arbitration Trial Between CEL-SCI and Clinical Research Organization inVentiv
Business Wire - Tue Jan 06, 7:02AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that the trial in its ongoing arbitration against inVentiv Clinical, LLC (f/k/a PharmaNet, LLC and PharmaNet GmbH (f/k/a PharmaNet AG)), a clinical research organization, is currently scheduled for May 4, 2015.
CVM: 0.84 (-0.01)
Traders Get Bullish on Shares of CEL-SCI, Shares Up 8.5% (CVM)
Comtex SmarTrend(R) - Mon Jan 05, 11:35AM CST
CEL-SCI (AMEX:CVM) is one of today's best performing penny stocks, up 8.5% to $0.67 on 1.1x average daily volume. Thus far today, CEL-SCI has traded 308,000 shares, vs. average volume of 283,000 shares per day. The stock has outperformed the Dow (8.5% to the Dow's -1.7%) and outperformed the S&P 500 (8.5% to the S&P's -1.7%) during today's trading.
CVM: 0.84 (-0.01)
Cell-Sci updates Phase 3 enrollment numbers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 9:53AM CST
CVM: 0.84 (-0.01)
CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold over 2013 in its Phase III Head and Neck Cancer Trial
Business Wire - Mon Jan 05, 7:31AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that in 2014 it enrolled close to 200 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This annual enrollment represents an eight-fold increase over enrollment of 24 patients in 2013, the year during which CEL-SCI dismissed its prior clinical research organization (CRO) and replaced it with new CROs, Aptiv and Ergomed. Twenty one (21) patients were enrolled in the study during the month of December.
CVM: 0.84 (-0.01)
CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments
Business Wire - Tue Dec 23, 3:30PM CST
CEL-SCI Corporation (NYSE MKT: CVM) reported financial results today for the fiscal year ended September 30, 2014. The Company also reported key clinical and corporate developments achieved during, and subsequent to, fiscal 2014.
CVM: 0.84 (-0.01)
